DOI:
10.1055/s-00000005
Aktuelle Rheumatologie
LinksClose Window
References
Goldsmith SR, Saif Ur Rehman S, Shirai CL. et al.
Resolution of secondary hemophagocytic lymphohistiocytosis after treatment with the JAK1/2 inhibitor ruxolitinib.
Blood Adv 2019;
3: 4131-4135
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.